Compare FNWB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | CTMX |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | United States |
| Employees | 242 | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.5M | 716.9M |
| IPO Year | 2012 | 2015 |
| Metric | FNWB | CTMX |
|---|---|---|
| Price | $10.35 | $2.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $13.50 | $12.10 |
| AVG Volume (30 Days) | 24.7K | ★ 3.7M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 36.00 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $176,000.00 | ★ $76,201,000.00 |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | $7.61 |
| P/E Ratio | $258.13 | ★ $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.25 | $2.00 |
| 52 Week High | $12.52 | $8.21 |
| Indicator | FNWB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 34.64 |
| Support Level | $9.55 | N/A |
| Resistance Level | $10.38 | $3.93 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 29.68 | 10.25 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It offers various products and services, such as commercial business loans, multi-family real estate loans, auto and consumer loans, transaction accounts, savings and money market accounts, online banking services, etc., focused on the lending, deposit, and money movement needs of individuals, businesses and nonprofit organizations. The Group's operations are mainly focused on serving various communities in Washington State, U.S. Substantially all of its income is derived from a diverse base of commercial, mortgage, and consumer lending activities and investments.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.